the galcanezumab phase 3 studies for migraine prevention, oral CGRP
receptor antagonists were investigational products.
who were enrolled in any other clinical trial involving an
investigational product were excluded from participation in
galcanezumab clinical trials.1
safety and efficacy of concomitant use of galcanezumab with oral CGRP
receptor antagonists is unknown.
for Migraine Prevention
has been studied in migraine prevention.2-4
is indicated for the prophylaxis of migraine in adults who have at
least 4 migraine days per month.5
is a humanized IgG4 mAb that
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of
galcanezumab for the prevention of episodic migraine: results of the
EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia.
Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab
for the prevention of episodic migraine: the EVOLVE-1 randomized
clinical trial. JAMA Neurol. 2018;75(9):1080-1088.
Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic
migraine: the randomized, double-blind, placebo-controlled REGAIN
study. Neurology. 2018;91(24):e2211-e2221.
Emgality [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
= calcitonin gene-related peptide
= immunoglobulin G (subclass) 4
= monoclonal antibody
medicinal product is subject to additional monitoring. This will
allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions.